€6.98
1.22% today
Xetra, May 15, 05:35 pm CET
ISIN
DE0005664809
Symbol
EVT
Index
Sector
Industry

Evotec Stock price

€6.98
+1.03 17.36% 1M
-3.49 33.37% 6M
-1.22 14.87% YTD
-3.50 33.44% 1Y
-17.26 71.22% 3Y
-16.20 69.91% 5Y
+3.03 76.65% 10Y
Xetra, Closing price Thu, May 15 2025
-0.09 1.22%
ISIN
DE0005664809
Symbol
EVT
Index
Sector
Industry

Key metrics

Market capitalization €1.25b
Enterprise Value €1.36b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.73
P/S ratio (TTM) P/S ratio 1.59
P/B ratio (TTM) P/B ratio 1.38
Revenue growth (TTM) Revenue growth 1.50%
Revenue (TTM) Revenue €788.22m
EBIT (operating result TTM) EBIT €-127.99m
Free Cash Flow (TTM) Free Cash Flow €-65.86m
Cash position €371.44m
EPS (TTM) EPS €-1.17
P/E forward negative
P/S forward 1.47
EV/Sales forward 1.60
Show more

Is Evotec a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Evotec Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Evotec forecast:

5x Buy
56%
4x Hold
44%

Analyst Opinions

9 Analysts have issued a Evotec forecast:

Buy
56%
Hold
44%

Financial data from Evotec

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
788 788
1% 1%
100%
- Direct Costs 681 681
10% 10%
86%
132 132
15% 15%
17%
- Selling and Administrative Expenses 190 190
10% 10%
24%
- Research and Development Expense 45 45
32% 32%
6%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -128 -128
55% 55%
-16%
Net Profit -207 -207
128% 128%
-26%

In millions EUR.

Don't miss a Thing! We will send you all news about Evotec directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evotec Stock News

AD HOC NEWS
9 days ago
Evotec SE / DE0005664809
AD HOC NEWS
10 days ago
Der Pharmawirkstoffforscher und -entwickler Evotec DE0005664809 hat einen schwächeren Jahresauftakt verzeichnet.
More Evotec News

Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Head office Germany
CEO Christian Wojczewski
Employees 4,827
Founded 1993
Website evotec.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today